DANTROLENE SODIUM
CENTRAL MUSCLE RELAXANTS · MUSCLE SPASM ·+4
ELITE LABORATOR
Drug class
Dantrolene
Dantrolene is a specific active pharmaceutical ingredient rather than a broad therapeutic drug class; pharmacologically, it represents the prototypical direct-acting skeletal muscle relaxant and ryanodine receptor antagonist. Read more about Dantrolene
13 drugs in this class 11 manufacturers
Drugs in Dantrolene
DANTROLENE SODIUM
CENTRAL MUSCLE RELAXANTS · MUSCLE SPASM ·+4
AHP
DANTROLENE SODIUM
CENTRAL MUSCLE RELAXANTS · MUSCLE SPASM ·+4
Amneal Pharmaceuticals
DANTROLENE SODIUM
CENTRAL MUSCLE RELAXANTS · MALIGNANT HYPERTHERMIA ·+1
Hikma Pharmaceuticals USA
Filter & compare in the drug finder →
Opens the drug finder with Dantrolene preselected. Add indication or manufacturer filters there.
Dantrolene is a specific active pharmaceutical ingredient rather than a broad therapeutic drug class; pharmacologically, it represents the prototypical direct-acting skeletal muscle relaxant and ryanodine receptor antagonist.
It exerts its therapeutic effect peripherally by binding to ryanodine receptor 1 channels, thereby inhibiting calcium release from the sarcoplasmic reticulum into the myoplasm and uncoupling excitation-contraction processes in skeletal muscle fibers.
Clinically, intravenous formulations are essential for the emergency management and prophylaxis of malignant hyperthermia crises, while oral forms are indicated to manage chronic muscle spasticity secondary to upper motor neuron disorders, including stroke, cerebral palsy, multiple sclerosis, and spinal cord injury.
-
fda.gov
Dantrolene is a specific active pharmaceutical ingredient rather than a broad therapeutic drug class; pharmacologically, it represents the prototypical direct-acting skeletal muscle relaxant and ryanodine receptor antagonist
-
fda.gov
Dantrolene is a specific active pharmaceutical ingredient rather than a broad therapeutic drug class; pharmacologically, it represents the prototypical direct-acting skeletal muscle relaxant and ryanodine receptor antagonist It exerts its therapeutic effect peripherally by binding to ryanodine receptor 1 channels, thereby inhibiting calcium release from the sarcoplasmic reticulum into the myoplasm and uncoupling excitation-contraction processes in skeletal muscle fibers Clinically, intravenous f...
-
fda.gov
It exerts its therapeutic effect peripherally by binding to ryanodine receptor 1 channels, thereby inhibiting calcium release from the sarcoplasmic reticulum into the myoplasm and uncoupling excitation-contraction processes in skeletal muscle fibers
-
nih.gov
Clinically, intravenous formulations are essential for the emergency management and prophylaxis of malignant hyperthermia crises, while oral forms are indicated to manage chronic muscle spasticity secondary to upper motor neuron disorders, including stroke, cerebral palsy, multiple sclerosis, and spinal cord injury
-
nih.gov
Clinically, intravenous formulations are essential for the emergency management and prophylaxis of malignant hyperthermia crises, while oral forms are indicated to manage chronic muscle spasticity secondary to upper motor neuron disorders, including stroke, cerebral palsy, multiple sclerosis, and spinal cord injury
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.